当前位置: 首页 >> 检索结果
381. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.
作者: Riad Salem.;Andrew C Gordon.;Samdeep Mouli.;Ryan Hickey.;Joseph Kallini.;Ahmed Gabr.;Mary F Mulcahy.;Talia Baker.;Michael Abecassis.;Frank H Miller.;Vahid Yaghmai.;Kent Sato.;Kush Desai.;Bartley Thornburg.;Al B Benson.;Alfred Rademaker.;Daniel Ganger.;Laura Kulik.;Robert J Lewandowski.
来源: Gastroenterology. 2016年151卷6期1155-1163.e2页
Conventional transarterial chemoembolization (cTACE) is used to treat patients with hepatocellular carcinoma (HCC). Radioembolization is a minimally invasive procedure that involves implantation of radioactive micron-sized particles loaded with yttrium-90 (Y90) inside the blood vessels that supply a tumor. We performed a randomized, phase 2 study to compare the effects of cTACE and Y90 radioembolization in patients with HCC.
382. In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.
作者: Jeffrey B Schwimmer.;Joel E Lavine.;Laura A Wilson.;Brent A Neuschwander-Tetri.;Stavra A Xanthakos.;Rohit Kohli.;Sarah E Barlow.;Miriam B Vos.;Saul J Karpen.;Jean P Molleston.;Peter F Whitington.;Philip Rosenthal.;Ajay K Jain.;Karen F Murray.;Elizabeth M Brunt.;David E Kleiner.;Mark L Van Natta.;Jeanne M Clark.;James Tonascia.;Edward Doo.; .
来源: Gastroenterology. 2016年151卷6期1141-1154.e9页
No treatment for nonalcoholic fatty liver disease (NAFLD) has been approved by regulatory agencies. We performed a randomized controlled trial to determine whether 52 weeks of cysteamine bitartrate delayed release (CBDR) reduces the severity of liver disease in children with NAFLD.
383. Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal Cancer.
作者: Toshiaki Watanabe.;Yoichi Ajioka.;Keiichi Mitsuyama.;Kenji Watanabe.;Hiroyuki Hanai.;Hiroshi Nakase.;Reiko Kunisaki.;Keiji Matsuda.;Ryuichi Iwakiri.;Nobuyuki Hida.;Shinji Tanaka.;Yoshiaki Takeuchi.;Kazuo Ohtsuka.;Kazunari Murakami.;Kiyonori Kobayashi.;Yasushi Iwao.;Masakazu Nagahori.;Bunei Iizuka.;Keisuke Hata.;Masahiro Igarashi.;Ichiro Hirata.;Shin-Ei Kudo.;Takayuki Matsumoto.;Fumiaki Ueno.;Gen Watanabe.;Masahiro Ikegami.;Yoko Ito.;Koji Oba.;Eisuke Inoue.;Naoki Tomotsugu.;Toru Takebayashi.;Kenichi Sugihara.;Yasuo Suzuki.;Mamoru Watanabe.;Toshifumi Hibi.
来源: Gastroenterology. 2016年151卷6期1122-1130页
A random biopsy is recommended for surveillance of ulcerative colitis (UC)-associated colorectal cancer. However, a targeted biopsy might be more effective. We conducted a randomized controlled trial to compare rates of neoplasia detection by targeted vs random biopsies in patients with UC.
384. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
作者: Anthony Lembo.;Mark Pimentel.;Satish S Rao.;Philip Schoenfeld.;Brooks Cash.;Leonard B Weinstock.;Craig Paterson.;Enoch Bortey.;William P Forbes.
来源: Gastroenterology. 2016年151卷6期1113-1121页
Few treatments have demonstrated efficacy and safety for diarrhea-predominant irritable bowel syndrome (IBS-D). A phase 3, randomized, double-blind, placebo-controlled trial was performed to evaluate the safety and efficacy of repeat treatment with the nonsystemic antibiotic rifaximin.
385. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
作者: Mariya Markova.;Olga Pivovarova.;Silke Hornemann.;Stephanie Sucher.;Turid Frahnow.;Katrin Wegner.;Jürgen Machann.;Klaus Jürgen Petzke.;Johannes Hierholzer.;Ralf Lichtinghagen.;Christian Herder.;Maren Carstensen-Kirberg.;Michael Roden.;Natalia Rudovich.;Susanne Klaus.;Ralph Thomann.;Rosemarie Schneeweiss.;Sascha Rohn.;Andreas F H Pfeiffer.
来源: Gastroenterology. 2017年152卷3期571-585.e8页
Nonalcoholic fatty liver disease (NAFLD) is associated with increased risk of hepatic, cardiovascular, and metabolic diseases. High-protein diets, rich in methionine and branched chain amino acids (BCAAs), apparently reduce liver fat, but can induce insulin resistance. We investigated the effects of diets high in animal protein (AP) vs plant protein (PP), which differ in levels of methionine and BCAAs, in patients with type 2 diabetes and NAFLD. We examined levels of liver fat, lipogenic indices, markers of inflammation, serum levels of fibroblast growth factor 21 (FGF21), and activation of signaling pathways in adipose tissue.
386. Colon Hypersensitivity to Distension, Rather Than Excessive Gas Production, Produces Carbohydrate-Related Symptoms in Individuals With Irritable Bowel Syndrome.
作者: Giles Major.;Sue Pritchard.;Kathryn Murray.;Jan Paul Alappadan.;Caroline L Hoad.;Luca Marciani.;Penny Gowland.;Robin Spiller.
来源: Gastroenterology. 2017年152卷1期124-133.e2页
Poorly digested, fermentable carbohydrates may induce symptoms of irritable bowel syndrome (IBS) via unclear mechanisms. We performed a randomized trial with magnetic resonance imaging (MRI) analysis to investigate correlations between symptoms and changes in small- and large-bowel contents after oral challenge.
387. Addition of Lubiprostone to polyethylene glycol(PEG) enhances the quality & efficacy of colonoscopy preparation: a randomized, double-blind, placebo controlled trial.
作者: Rupa Banerjee.;Hrushikesh Chaudhari.;Nirish Shah.;Arjunan Saravanan.;Manu Tandan.;D Nageshwar Reddy.
来源: BMC Gastroenterol. 2016年16卷1期133页
Adequate bowel preparation is an essential prerequisite for complete mucosal visualization during colonoscopy. Polyethylene glycol (PEG) solutions are commonly used. However the large volume of the solution is often poorly tolerated. Addition of Lubiprostone (LB) could improve the adequacy of standard PEG preparation & reduce requirement. The aims to assess adequacy of PEG preparation with addition of single dose LB (24mcg) vs placebo and efficacy of reduced dose PEG + LB compared with full dose PEG + LB.
388. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
作者: Paul Kwo.;Edward J Gane.;Cheng-Yuan Peng.;Brian Pearlman.;John M Vierling.;Lawrence Serfaty.;Maria Buti.;Stephen Shafran.;Paul Stryszak.;Li Lin.;Jacqueline Gress.;Stuart Black.;Frank J Dutko.;Michael Robertson.;Janice Wahl.;Lisa Lupinacci.;Eliav Barr.;Barbara Haber.
来源: Gastroenterology. 2017年152卷1期164-175.e4页
Patients infected with hepatitis C virus (HCV) genotype 1, 4, or 6, with or without cirrhosis, previously treated with peg-interferon and ribavirin, are a challenge to treat. We performed a phase 3 randomized controlled open-label trial to assess the effects of 12 or 16 weeks of treatment with once-daily elbasvir (an HCV NS5A inhibitor, 50 mg) and grazoprevir (an HCV NS3/4A protease inhibitor, 100 mg), in a fixed-dose combination tablet, with or without twice-daily ribavirin, in this patient population.
389. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.
作者: Christophe Bureau.;Dominique Thabut.;Frédéric Oberti.;Sébastien Dharancy.;Nicolas Carbonell.;Antoine Bouvier.;Philippe Mathurin.;Philippe Otal.;Pauline Cabarrou.;Jean Marie Péron.;Jean Pierre Vinel.
来源: Gastroenterology. 2017年152卷1期157-163页
There is controversy over the ability of transjugular intrahepatic portosystemic shunts (TIPS) to increase survival times of patients with cirrhosis and refractory ascites. The high rate of shunt dysfunction with the use of uncovered stents counteracts the benefits of TIPS. We performed a randomized controlled trial to determine the effects of TIPS with stents covered with polytetrafluoroethylene in these patients.
390. Effectiveness of Pelvic Physiotherapy in Children With Functional Constipation Compared With Standard Medical Care.
作者: Marieke L van Engelenburg-van Lonkhuyzen.;Esther M J Bols.;Marc A Benninga.;Wim A Verwijs.;Rob A de Bie.
来源: Gastroenterology. 2017年152卷1期82-91页
Functional constipation (FC) is a common childhood problem often related to pelvic floor muscle dysfunction. We compared the effectiveness of pelvic physiotherapy (PPT) vs standard medical care (SMC) in children with FC.
391. Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
作者: Francis K L Chan.;Moe Kyaw.;Tetsuya Tanigawa.;Kazuhide Higuchi.;Kazuma Fujimoto.;Pui Kuan Cheong.;Vivian Lee.;Yoshikazu Kinoshita.;Yuji Naito.;Toshio Watanabe.;Jessica Y L Ching.;Kelvin Lam.;Angeline Lo.;Heyson Chan.;Rashid Lui.;Raymond S Y Tang.;Yasuhisa Sakata.;Yee Kit Tse.;Toshihisa Takeuchi.;Osamu Handa.;Hiroko Nebiki.;Justin C Y Wu.;Takashi Abe.;Tsuyoshi Mishiro.;Siew C Ng.;Tetsuo Arakawa.
来源: Gastroenterology. 2017年152卷1期105-110.e1页
It is not clear whether H2-receptor antagonists (H2RAs) reduce the risk of gastrointestinal (GI) bleeding in aspirin users at high risk. We performed a double-blind randomized trial to compare the effects of a proton pump inhibitor (PPI) vs a H2RA antagonist in preventing recurrent upper GI bleeding and ulcers in high-risk aspirin users.
392. Effect of mobile phone reminder messages on adherence of stent removal or exchange in patients with benign pancreaticobiliary diseases: a prospectively randomized, controlled study.
作者: Yong Gu.;Limei Wang.;Lina Zhao.;Zhiguo Liu.;Hui Luo.;Qin Tao.;Rongchun Zhang.;Shuixiang He.;Xiangping Wang.;Rui Huang.;Linhui Zhang.;Yanglin Pan.;Xuegang Guo.
来源: BMC Gastroenterol. 2016年16卷1期105页
Plastic and covered metal stents need to be removed or exchanged within appropriate time in case of undesirable complications. However, it is not uncommon that patients do not follow the recommendation for further stent management after Endoscopic Retrograde Cholangiopancreatography (ERCP). The effect of short message service (SMS) intervention monthly on the stent removal/exchange adherence in patients after ERCP is unknown at this time.
393. Alcohol Consumption and Multiple Dysplastic Lesions Increase Risk of Squamous Cell Carcinoma in the Esophagus, Head, and Neck.
作者: Chikatoshi Katada.;Tetsuji Yokoyama.;Tomonori Yano.;Kazuhiro Kaneko.;Ichiro Oda.;Yuichi Shimizu.;Hisashi Doyama.;Tomoyuki Koike.;Kohei Takizawa.;Motohiro Hirao.;Hiroyuki Okada.;Takako Yoshii.;Kazuo Konishi.;Takenori Yamanouchi.;Takashi Tsuda.;Tai Omori.;Nozomu Kobayashi.;Tadakazu Shimoda.;Atsushi Ochiai.;Yusuke Amanuma.;Shinya Ohashi.;Tomonari Matsuda.;Hideki Ishikawa.;Akira Yokoyama.;Manabu Muto.
来源: Gastroenterology. 2016年151卷5期860-869.e7页
Some patients develop multiple squamous cell carcinomas (SCCs) in the upper aerodigestive tract, attributed to field cancerization; alcohol consumption has been associated with this process. We examined the association between multiple areas of dysplastic squamous epithelium with the development of SCC of the esophagus or head and neck cancer, as well as alcohol consumption and smoking.
394. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
作者: Eric Lawitz.;Nancy Reau.;Federico Hinestrosa.;Mordechai Rabinovitz.;Eugene Schiff.;Aasim Sheikh.;Ziad Younes.;Robert Herring.;K Rajender Reddy.;Tram Tran.;Michael Bennett.;Ronald Nahass.;Jenny C Yang.;Sophia Lu.;Hadas Dvory-Sobol.;Luisa M Stamm.;Diana M Brainard.;John G McHutchison.;Brian Pearlman.;Mitchell Shiffman.;Trevor Hawkins.;Michael Curry.;Ira Jacobson.
来源: Gastroenterology. 2016年151卷5期893-901.e1页
The best regimen to re-treat patients who do not respond to direct-acting antivirals (DAAs) and the feasibility of further shortening regimens is unclear. We assessed the efficacy and safety of the combination of the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 in patients with hepatitis C virus genotype 1 infection.
395. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
作者: Edward J Gane.;Kris V Kowdley.;David Pound.;Catherine A M Stedman.;Mitchell Davis.;Kyle Etzkorn.;Stuart C Gordon.;David Bernstein.;Gregory Everson.;Maribel Rodriguez-Torres.;Naoky Tsai.;Omer Khalid.;Jenny C Yang.;Sophia Lu.;Hadas Dvory-Sobol.;Luisa M Stamm.;Diana M Brainard.;John G McHutchison.;Myron Tong.;Raymond T Chung.;Kimberly Beavers.;John E Poulos.;Paul Y Kwo.;Mindie H Nguyen.
来源: Gastroenterology. 2016年151卷5期902-909页
Studies are needed to determine the optimal regimen for patients with chronic hepatitis C virus (HCV) genotype 2, 3, 4, or 6 infections whose prior course of antiviral therapy has failed, and the feasibility of shortening treatment duration. We performed a phase 2 study to determine the efficacy and safety of the combination of the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 in these patients.
396. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
作者: Carol A Burke.;Evelien Dekker.;N Jewel Samadder.;Elena Stoffel.;Alfred Cohen.
来源: BMC Gastroenterol. 2016年16卷1期87页
Molecular studies suggest inhibition of colorectal mucosal polyamines (PAs) may be a promising approach to prevent colorectal cancer (CRC). Inhibition of ornithine decarboxylase (ODC) using low-dose eflornithine (DFMO, CPP-1X), combined with maximal PA export using low-dose sulindac, results in greatly reduced levels of normal mucosal PAs. In a clinical trial, this combination (compared with placebo) reduced the 3-year incidence of subsequent high-risk adenomas by >90 %. Familial Adenomatous Polyposis (FAP) is characterized by marked up-regulation of ODC in normal intestinal epithelial and adenoma tissue, and therefore PA reduction might be a potential strategy to control progression of FAP-related intestinal polyposis. CPP FAP-310, a randomized, double-blind, Phase III trial was designed to examine the safety and efficacy of sulindac and DFMO (alone or in combination) for preventing a clinically relevant FAP-related progression event in individuals with FAP.
397. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
作者: Ju Yup Lee.;Nayoung Kim.;Kyung Sik Park.;Hyun Jin Kim.;Seon Mee Park.;Gwang Ho Baik.;Ki-Nam Shim.;Jung Hwan Oh.;Suck Chei Choi.;Sung Eun Kim.;Won Hee Kim.;Seon-Young Park.;Gwang Ha Kim.;Bong Eun Lee.;Yunju Jo.;Su Jin Hong.
来源: BMC Gastroenterol. 2016年16卷1期79页
The <80 % Helicobacter pylori eradication rate with sequential therapy is unsatisfactory. Modified bismuth quadruple therapy, replacing metronidazole with amoxicillin, could be promising because H. pylori resistance to tetracycline or to amoxicillin is relatively low. A 14-day modified bismuth quadruple protocol as first-line H. pylori treatment was compared with 10-day sequential therapy.
398. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
作者: Edward Gane.;Fred Poordad.;Stanley Wang.;Armen Asatryan.;Paul Y Kwo.;Jacob Lalezari.;David L Wyles.;Tarek Hassanein.;Humberto Aguilar.;Benedict Maliakkal.;Ran Liu.;Chih-Wei Lin.;Teresa I Ng.;Jens Kort.;Federico J Mensa.
来源: Gastroenterology. 2016年151卷4期651-659.e1页
The combination of ABT-493 (NS3/4A protease inhibitor) plus ABT-530 (NS5A inhibitor) has shown high rates of sustained virologic response at post-treatment week 12 (SVR12) in noncirrhotic patients infected with hepatitis C virus (HCV) genotypes (GTs) 1-6. We describe 2 open-label phase 2 studies investigating the efficacy and safety of ABT-493 plus ABT-530 with or without ribavirin (RBV) in GT1- or GT3-infected patients with compensated cirrhosis.
399. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
作者: Vinod S Hegade.;Stuart F W Kendrick.;Robert L Dobbins.;Sam R Miller.;Duncan Richards.;James Storey.;George Dukes.;Kim Gilchrist.;Susan Vallow.;Graeme J Alexander.;Margaret Corrigan.;Gideon M Hirschfield.;David E J Jones.
来源: BMC Gastroenterol. 2016年16卷1期71页
Pruritus (itch) is a symptom commonly experienced by patients with cholestatic liver diseases such as primary biliary cholangitis (PBC, previously referred to as primary biliary cirrhosis). Bile acids (BAs) have been proposed as potential pruritogens in PBC. The ileal bile acid transporter (IBAT) protein expressed in the distal ileum plays a key role in the enterohepatic circulation of BAs. Pharmacological inhibition of IBAT with GSK2330672 may reduce BA levels in the systemic circulation and improve pruritus.
400. A randomized controlled trial of an educational video to improve quality of bowel preparation for colonoscopy.
作者: Jin-Seok Park.;Min Su Kim.;HyungKil Kim.;Shin Il Kim.;Chun Ho Shin.;Hyun Jung Lee.;Won Seop Lee.;Soyoung Moon.
来源: BMC Gastroenterol. 2016年16卷1期64页
High-quality bowel preparation is necessary for colonoscopy. A few studies have been conducted to investigate improvement in bowel preparation quality through patient education. However, the effect of patient education on bowel preparation has not been well studied.
|